PHRM 562 | Pharmacodynamics and Pharmacokinetics Interface
PHRM 585 | Pharmacokinetics
2010 | Foreign Pharmacy Graduate Examination Certificate (FPGEC), National Association of Boards of Pharmacy
2006 | Postdoctoral Fellow, Department of Medicine, University of Saskatchewan, Canada
2006 | Doctor of Philosophy, Pharmacy, Drug Metabolism, and Pharmacokinetics, University of Saskatchewan, Canada
2002 | Master of Science, Analytical Chemistry, College of Pharmacy, University of Tanta, Egypt
1995 | Postgraduate Diploma, Analytical Chemistry, College of Pharmacy, University of Tanta, Egypt
1993 | Bachelor of Pharmaceutical Sciences, College of Pharmacy, University of Tanta, Egypt
Areas of Research & Specialization
My research interests revolve around minimizing toxicity and/or drug interactions of xenobiotics through better understanding of their effect on drug metabolizing enzymes (DME), especially Cytochrome P450 (CYP) enzymes. Although CYP enzymes normally generate metabolites with diminished biological activity, there are numerous examples where these enzymes mediate the formation of reactive intermediates from chemically inert agents. These reactive metabolites play a key step in initiating cellular damage and cancers. Modification of the activity or expression level of CYP enzymes through exposure to environmental toxins, drugs, or even herbal remedies could potentially affect the clinical outcome of concomitantly-administered drugs. My research interest focuses on identifying the role of CYP enzymes in toxicity induced by drugs, herbal remedies and environmental toxins. Along with the mission of Pacific University and the School of Pharmacy, the outcome of this research will be utilized to advance the level of pharmaceutical care within the community and improve health care literacy among patients. The following projects are being conducted in our research facility in HPC2 and/or in collaboration with scientists from Oregon Health and Science University and University of Saskatchewan (Canada).
Project 1: Studying the Effect of Herbal Remedies on Drug Metabolizing Enzymes
Several animal studies (e.g. those of my postdoctoral research) and human clinical trials have demonstrated that consumption of some natural products decreases morbidity associated with chronic disease. Therefore, public consumption of these products is expected to increase. As a pharmacist, I find the increased use of natural products and nutraceuticals without consultation from the physician or pharmacist is concerning. Therefore in order to provide evidence-based consultation, more understanding of how these products (and their metabolites) affect the activity of drug metabolizing enzymes (DME) is needed. This research focuses on filling this need by studying the bidirectional relationship between natural products and physiological systems. Induction or inhibition of DME by natural products can potentially affect bioavailability, and consequently, toxic effect of concomitantly administered medications.
Project 2: Studying the Effect of Herbal Remedies on Arachidonic Acid Metabolism as a Target for Hypertension Treatment
Substantial evidences indicate that metabolites of Arachidonic acid (AA) via kidney Cytochrome P450 (CYP) enzymes play a critical role in regulation of renal vascular tone, sodium transport, and may participate in the pathogenesis of hypertension. 20-hydroxyeicosatetraenoic acid (20-HETE) is one of the major AA products of CYP metabolism in the kidney. In the renal and peripheral vasculature, 20-HETE is a potent vasoconstrictor that acts by depolarizing the vascular smooth muscles (VSM) cells. Several studies have shown that the vasoconstriction response to vasoconstrictor agonists such as angiotensin II and norepinephrin is secondary to stimulating the endogenous production of 20-HETE in renal VSM cells. In the rat; CYP4A1, CYP4A2 and CYP4A3 were found to exhibit the highest catalytic activity for the formation of 20-HETE. Therefore, specific inhibition of these CYP enzymes could be a potential target for prevention and/or treatment of hypertension mediated by elevation of 20-HETE formation. Our lab is currently investigating the antihypertensive potential of Sulforaphane, the main active ingredient of broccoli sprouts and cruciferous vegetables. We will investigate the potential inhibitory effect of Sulforaphane (SF) on the activity and expression of CYP enzymes involved in 20-HETE formation.
Selected Publications and Presentations
Elbarbry F. Introduction to Toxicology. In: Karimi R, editor. Biomedical and Pharmaceutical Sciences with Patient Care Correlations. 2014
Elbarbry F and Karimi R. Introduction to Pharmacokinetics. In: Karimi R, editor. Biomedical and Pharmaceutical Sciences with Patient Care Correlations. Jones & Bartlett Learning, 2014.
Ebied WM, Hytham AM, Elbarbry FA. Production and analysis of a biosimilar erythropoietin in Egypt. Biosimilars. 2014; 4: 11-22.
Elbarbry F, Vermehren Schmaedick A, Balkowiec A. Modulation of Arachidonic Acid Metabolism in the Rat Kidney by Sulforaphane: Implications for Regulation of Blood Pressure. ISRN-Pharmacology. 2014, Article ID 683508
Ahmed H, Elbarbry F, Clark B. Mixed Micellar Electrokinetic Chromatographic Analysis of Colistin, a Polypeptide Antibiotic, Using Laser-Induced Fluorescence Detection. AJAC. 3:233-241. 2012.
Elbarbry F, Ragheb A, Marfleet T, and Shoker A. Modulation of Hepatic Drug Metabolizing Enzymes by Dietary Doses of Thymoquinone in Female New Zealand White Rabbits. Phytotherapy Research. 2012.
Karimi R, Elbarbry F, Fortner J. Integrative Student Learning: An Effective Team Learning Activity in a Learner-Centered Paradigm. Innovations in Pharmacy. 2(4):1-16. 2011
Elbarbry F and Elrody N. Potential Health Benefits of Sulforaphane: A Review of the Experimental, Clinical and Epidemiological Evidences and Underlying Mechanisms. JMPR. 5(4): 473-484. 2011
Elbarbry F, Chibbar R, Marfleet T, and Shoker A. Cyclosporine-induced changes in drug metabolizing enzymes in hyperlipemic rabbit kidneys could explain its toxicity. Xenobiotica. 40(11):772-81. 2011
Karimi R, Arendt C, Elbarbry F, Roberts S. Learning bridge: curricular integration of didactic and experiential education. AJPE. 74(3): article 48. 2010
Ragheb A, Attia A, Elbarbry F, Prasad K, Shoker A. Attenuated combined action of cyclosporine a and hyperlipidemia on atherogenesis in rabbits by thymoquinone. Evid Based Complement Alternat. Med. 2010
Elbarbry F, Attia A, Shoker A. Validation of a new HPLC method for determination of midazolam and its metabolites: application to determine its pharmacokinetics in human and measure hepatic CYP3A activity in rabbits. J Pharm Biomed Anal. 50(5):987-93. 2009
Ragheb A, Attia A, Elbarbry F, Shoker A. The protective effect of thymoquinone, an anti-oxidant and anti-inflammatory agent, against renal injury: a review. SJKDT. 20(5): 741-752. 2009
Elbarbry F and Alcorn J. Ontogeny of glutathione and glutathione-related antioxidant enzymes in rat liver. Research in Veterinary Sciences. 87(2):242-244. 2009
Ragheb A, Elbarbry F, Prasad K, Mohammed A, Shoker A. Attenuation of the development of hypercholesterolemic atherosclerosis by thymoquinone. Int. J. Angiol. 17(4):186-192. 2008
Elbarbry F, Marfleet T, and Shoker A. Drug-drug interactions with immunosuppressive agents: review of the in vitro functional assays and role of cytochrome P450 enzymes.Transplantation. 85(9), 1222-1229. 2008
Elbarbry F and Shoker A. Liquid chromatographic determination of mycophenolic acid and its metabolites in human kidney transplant plasma: pharmacokinetic application. J Chromatogr. B.859(2):276-81. 2007
Elbarbry F and Shoker A. Therapeutic drug measurement of mycophenolic acid derivatives in transplant patients. Clinical Biochemistry. 40(11):752-64. 2007
Elbarbry F, McNamara P, and Alcorn J. Ontogeny of hepatic CYP1A2 and CYP2E1 expression in rat. J Biochem. Mol Toxicol. 21(1):41-50. 2007
Elbarbry F, Eldawy M, Mabrouk M. Determination of the analgesic components of Spasmomigraine tablet by liquid chromatography with ultraviolet detection. J AOAC Int. 90(1): 94-101. 2007
Alcorn J, Elbarbry F, and McNamara P. Evaluation of the assumptions of an ontogeny model of rat hepatic cytochrome P450 activity. Drug Metabolism and Disposition. 35(12):2225-31. 2007
Elbarbry F and Shoker A. Simple high performance liquid chromatographic assay for mycophenolic acid in renal transplant patients. J Pharm. Biomed Anal. 43(2): 788-92. 2007
Elbarbry F, Wilby K, and Alcorn J. Validation of a HPLC method for the determination of p-nitrophenol hydroxylase activity in rat hepatic microsomes. J Chromatogr. B. 834 (1-2): 199-203. 2006
Elbarbry F and Alcorn J. Maturation of Cytochrome P450 2E1 and Glutathione-S-Transferases, Pharmacokinetic Model Validation, J Pharm. Pharmaceutical Sci., 7(2): 284-302. 2004
Eldawy M, Mabrouk M, and El-barbary F. Determination of chlorpheniramine maleate and tincture ipecac in dosage form by liquid chromatography with ultraviolet detection. J AOAC Int.86 (4): 675-80. 2003
Eldawy M, Mabrouk M, and El-barbary F. Liquid chromatographic determination of fluoxetine. J Pharm Biomed Anal. 30 (3), 561-71. 2002
Selected Platform Presentations
The 1st Annual International Conference on Pharmacology and Pharmacological Sciences (PHARMA 2013), Singapore: Modulation of Arachidonic Acid Metabolism, A potential Target for Hypertension Treatment (Best Research Paper and Oral Presentation). 2013
Pacific Author Reception. Hillsboro, OR: A story of success in getting grants and building collaborations. 2013.
Two-Slide, Get Acquainted Symposium. Forest Grove, Oregon, USA: New Targets for Hypertension Treatment. 2013.
The 7th Biennial Symposium on Polyamines In Parasites. Forest Grove, Oregon, USA: Cytochrome p450 Enzymes and Drug-Induced Toxicity; Role of Natural Products. 2012.
Professional Society of Pharmacists, Portland, Oregon, USA: Pharmacy Practice in Egypt. (Approved by Oregon Board of Pharmacy as 1 CE hour). 2012.
Pacific University School of Pharmacy Monthly Health and Sciences Seminars: Characterization of Cytochrome P450 Enzymes as New Targets for the Treatment of Hypertension. 2011.
Pacific University School of Pharmacy Monthly Health and Sciences Seminars: PhD and PharmD/PhD Feasibility Study (Co-presenter with John Harrelson). 2011.
Oregon Health and Sciences University (OHSU), Department of Physiology and Pharmacology, Oregon, USA: Ontogeny of Rat CYP2E1 and CYP1A2, and Development of a Pharmacokinetic Model. 2011.
First International Biotechnology Innovation Conference-Cairo, Egypt: Cyclosporine-induced Changes in Drug Metabolizing Enzymes in Hyperlipemic Rabbit Kidneys could explain its Toxicity. 2010.
Pacific University School of Pharmacy Faculty Development Workshops: Building your Teaching Dossier. 2010.
Pacific University School of Pharmacy Monthly Journal Clubs: Role of Arachidonic Acid Metabolism in Pathogenesis of Hypertension (presenter and organizer). 2010.
Pacific University School of Pharmacy Monthly Health and Sciences Seminars: Pharmacy Practice in Egypt. 2009.
Selected Poster Presentations
Stamper B, Buhler Harrelson J, Malhotra A, Roberts S, Elbarbry F, Rao D, Marlow C, Karimi R, and Devaud L. Development of online pharmacy prerequisites review tutorials for first year pharmacy students. American Association of Colleges of Pharmacy (AACP) Annual Meeting. Grapevine, TX 2014.
Hassan K, Elbarbry F, Stamper B. Comparing pharmacy education and practice in Iraq and the United States. American Association of Colleges of Pharmacy (AACP) Annual Meeting. Grapevine, TX 2014.
Doyle I, Elbarbry F. Area Under the Curve Comparison of Innovator vs. Generic Mycophenolate Mofetil in Renal Transplant Recipients. World Transplant Congress (WTC). San Francisco, CA. 2014.
Karimi R, Elbarbry F, Fortner J, Rao D, Roberts S. Science Applications for Patients, Pharmacists, and Scientists, Implemented by First Year Pharmacy Students. American Association of Colleges of Pharmacy (AACP) Annual Meeting. Chicago, IL 2013.
Karimi R, Elbarbry F, Fortner J. Integrative Learning and Assessment: An Effective Tool to Promote and Assess Student Learning. American Association of Colleges of Pharmacy (AACP) Annual Meeting. Seattle, WA. 2010.
Josef Bonnarens, Lonnie Anderson, Fawzy Elbarbry. First Year of PharmCAS-The Aftermath: A school Continued Journey Through the Admission Process. American Association of Colleges of Pharmacy (AACP) Annual Meeting. Seattle, WA. 2010.